報價延遲最少15分鐘:2025/01/21 18:56 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.96 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.83/2.17
|
|
企業價值
1.29B
|
| 資產負債 |
|
每股賬面淨值
9.66
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
492.05M
|
|
每股收益
6.54
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:56 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medicalaesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States. |